<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2163">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01600703</url>
  </required_header>
  <id_info>
    <org_study_id>Sitagliptin-REB-09-0428-B</org_study_id>
    <nct_id>NCT01600703</nct_id>
  </id_info>
  <brief_title>Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans</brief_title>
  <official_title>Sitagliptin (Â®Januvia) Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Frosst Canada Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies in both animals and humans has demonstrated that the hormone GLP-1 (glucagon
      like peptide 1) reduces intestinal production of lipoprotein particles. The investigators
      therefore hypothesise that the drug sitagliptin which prevents the breakdown of GLP-1 will
      reduce intestinal lipoprotein production in humans. The investigators are unable to
      speculate whether sitagliptin will affect hepatic lipoprotein production because of lack of
      of data from animal studies or in vitro data. Sitagliptin is already an approved treatment
      for type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each subject will be studied twice 4-6 weeks apart in random order in this single blinded
      study. In study A they will receive a single dose of sitagliptin 100mg od. In study B they
      will receive placebo. A nasoduodenal tube will be sited under fluoroscopic guidance the day
      prior to the study. On the day of the study regular liquid formula (Great shake plus) will
      be infused from 4am through the tube to maintain a constant fed state. A pancreatic clamp
      (octreotide with replacement glucose, insulin and growth hormone) along with
      saline/sitagliptin will be started at 7am. From 9am an iv bolus of deuterated-glycerol
      (d5-glycerol) along with a regular infusion of deuterated leucine (L-[5,5,5-2H3]. Regular
      blood samples will be drawn to assess lipoprotein kinetics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>The Primary Objective is to Examine the apoB48 Production Rate After Acute Oral Administration of 100mg Sitagliptin (Compared to Placebo), Under Conditions of a Pancreatic Clamp and a Steady State Fed State</measure>
    <time_frame>10 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>ApoB48 turnover was measured in a 10-hour kinetic study with in vivo tracer techniques and mathematical modeling to calculate production rates. Studies were performed under conditions of a pancreatic clamp and a steady state fed state in volunteers receiving single oral dose of either 100mg sitagliptin or matching placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Primary Objective is to Examine the apoB100 Production Rate After Acute Oral Administration of 100mg Sitagliptin (Compared to Placebo), Under Conditions of a Pancreatic Clamp and a Steady State Fed State</measure>
    <time_frame>10 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>ApoB100 turnover was measured in a 10-hour kinetic study with in vivo tracer techniques and mathematical modeling to calculate production rates. Studies were performed under conditions of a pancreatic clamp and a steady state fed state in volunteers receiving single oral dose of either 100mg sitagliptin or matching placebo.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg po</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100mg po single dose</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women, aged 18 to 60 years

          2. Body mass index 20 kg/m2 to 27 kg/m2

          3. Hemoglobin above 130g/L.

          4. Normal glucose tolerance in response to a 75g, 2-hr OGTT

        Exclusion Criteria:

          1. Subject has a history of hepatitis/hepatic disease that has been active within the
             previous two years.

          2. Any significant active (over the past 12 months) disease of the gastrointestinal,
             pulmonary, neurological, renal (Cr &gt; 1.5 mg/dL), genitourinary, hematological
             systems, or has severe uncontrolled treated or untreated hypertension (sitting
             diastolic BP &gt; 100 or systolic &gt; 180) or proliferative retinopathy

          3. History of diabetes or OGTT indicative of diabetes or impaired glucose tolerance.

          4. Any history of a MI or clinically significant, active, cardiovascular history
             including a history of arrhythmia's or conduction delays on ECG, unstable angina, or
             decompensated heart failure.

          5. Any laboratory values: AST &gt; 2x ULN; ALT &gt; 2x ULN TSH &gt; 6 mU/l

          6. Current addiction to alcohol or substances of abuse as determined by the
             investigator.

          7. Mental incapacity, unwillingness or language barrier precluding adequate
             understanding or cooperation

          8. Taking any prescription or non-prescription medications at the time of the study

          9. Having donated blood three months prior to and three months post study procedures

         10. A pregnancy test will be performed 1 to 3 days prior to each study in all female
             subjects. Those who test positive for pregnancy will be excluded.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Lewis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UHN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Xiao C, Dash S, Morgantini C, Patterson BW, Lewis GF. Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans. Diabetes. 2014 Jul;63(7):2394-401. doi: 10.2337/db13-1654. Epub 2014 Feb 28.</citation>
    <PMID>24584549</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>May 15, 2012</firstreceived_date>
  <firstreceived_results_date>March 24, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intestinal lipoprotein</keyword>
  <keyword>Apo B48 and apoB100</keyword>
  <keyword>Pancreatic clamp</keyword>
  <keyword>DPPIV inhibitor</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sitagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Local newspaper advertisement</recruitment_details>
      <pre_assignment_details>Screening, checking for inclusion criteria, obtaining written consents</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin</title>
          <description>100mg po
Sitagliptin: 100mg po single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin</title>
          <description>100mg po
Sitagliptin: 100mg po single dose</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="42.3" spread="2.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Canada</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="24.6" spread="0.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Glucose</title>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="4.9" spread="0.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Triglyceride</title>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1.2" spread="0.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Objective is to Examine the apoB48 Production Rate After Acute Oral Administration of 100mg Sitagliptin (Compared to Placebo), Under Conditions of a Pancreatic Clamp and a Steady State Fed State</title>
        <description>ApoB48 turnover was measured in a 10-hour kinetic study with in vivo tracer techniques and mathematical modeling to calculate production rates. Studies were performed under conditions of a pancreatic clamp and a steady state fed state in volunteers receiving single oral dose of either 100mg sitagliptin or matching placebo.</description>
        <time_frame>10 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo po single dose</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>sitagliptin 100 mg po single dose</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Primary Objective is to Examine the apoB48 Production Rate After Acute Oral Administration of 100mg Sitagliptin (Compared to Placebo), Under Conditions of a Pancreatic Clamp and a Steady State Fed State</title>
            <description>ApoB48 turnover was measured in a 10-hour kinetic study with in vivo tracer techniques and mathematical modeling to calculate production rates. Studies were performed under conditions of a pancreatic clamp and a steady state fed state in volunteers receiving single oral dose of either 100mg sitagliptin or matching placebo.</description>
            <units>ug/kg/d</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="122.9" spread="30.4"/>
                  <measurement group_id="O2" value="60.6" spread="12.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Primary Objective is to Examine the apoB100 Production Rate After Acute Oral Administration of 100mg Sitagliptin (Compared to Placebo), Under Conditions of a Pancreatic Clamp and a Steady State Fed State</title>
        <description>ApoB100 turnover was measured in a 10-hour kinetic study with in vivo tracer techniques and mathematical modeling to calculate production rates. Studies were performed under conditions of a pancreatic clamp and a steady state fed state in volunteers receiving single oral dose of either 100mg sitagliptin or matching placebo.</description>
        <time_frame>10 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo po single dose</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>sitagliptin 100 mg po single dose</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Primary Objective is to Examine the apoB100 Production Rate After Acute Oral Administration of 100mg Sitagliptin (Compared to Placebo), Under Conditions of a Pancreatic Clamp and a Steady State Fed State</title>
            <description>ApoB100 turnover was measured in a 10-hour kinetic study with in vivo tracer techniques and mathematical modeling to calculate production rates. Studies were performed under conditions of a pancreatic clamp and a steady state fed state in volunteers receiving single oral dose of either 100mg sitagliptin or matching placebo.</description>
            <units>mg/kg/d</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17.6" spread="1.8"/>
                  <measurement group_id="O2" value="20.4" spread="2.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>placebo 100mg po single dose</description>
        </group>
        <group group_id="E2">
          <title>Sitagliptin</title>
          <description>sitagliptin 100mg po single dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gary Lewis</name_or_title>
      <organization>University Health Network</organization>
      <phone>416-340-4270</phone>
      <email>gary.lewis@uhn.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
